As of Feb 27
| +0.23 / +1.93%|
The 9 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 25.00, with a high estimate of 32.00 and a low estimate of 19.00. The median estimate represents a +105.59% increase from the last price of 12.16.
The current consensus among 9 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.